Study of a C1 inhibitor medicine for HAE attacks
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a plasma-derived C1 esterase inhibitor to treat and prevent acute attacks in people with hereditary angioedema (HAE) types 1 or 2. It aims to see if the medicine can quickly relieve swelling episodes and reduce their frequency.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HAE type 1 or 2 (confirmed by a blood test).
- You have had at least 3 moderate or severe HAE attacks (not just on arms or legs) in the last 3 months if you are 18 or older; children 2-12 need at least 1 attack in the last 6 months.
- You must not have had an allergic reaction to C1 inhibitor products or blood/plasma products in the past.
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must use highly effective birth control during the study.
- You are willing to avoid certain HAE medicines (like Berinert, Cinryze, ecallantide, icatibant, or berotralstat) for at least 14 days before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if sebetralstat can prevent swelling attacks before medical procedures in people with HAE types I or II. You take the medicine short-term before your procedure to see if it helps protect you from an attack.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This study tests an oral medication that can be taken daily to prevent angioedema attacks and as a rescue treatment when attacks occur. It may help reduce the frequency and severity of swelling episodes.
This study looks at the genes that cause hereditary angioedema (HAE), a condition with sudden swelling in the hands, feet, face, or airways. By joining, you help doctors understand the disease better, which could lead to better care for you and others.
Hear when a new Acute Hereditary Angio Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.